Figure 3.
![Figure 3. Outline of treatment strategies in the type I interferonopathies. Dependent on the underlying pathological mechanism, therapeutic approaches in the type I interferonopathies might include blocking the generation (e.g., using reverse transcription inhibitors: https://clinicaltrials.gov/ct2/show/NCT02363452), sensing (e.g., cGAS inhibition by hydroxychloroquine [An et al., 2015]), or signaling (e.g., TBK1 inhibition [Hasan et al., 2015]) of putative self–nucleic acids engaging the type I interferon innate immune machinery and blocking of interferon itself (e.g., with anti–type I interferon antibodies), the IFNAR receptor, or the signaling cascades distal to interferon ligand binding (e.g., by JAK1 inhibition [Frémond et al., 2016]).](https://cdn.rupress.org/rup/content_public/journal/jem/213/12/10.1084_jem.20161596/6/jem_20161596_fig3.jpeg?Expires=1767731705&Signature=PYcG1jjX-kHtBRzGDQYiF0tHFMC28AVpSOWcsXOQF-mWPR067l7ASBdX-yh5vwxPk6V6ntwoPwEnpx-hSlEEYJMqmvu9l5LOUX99r9TAy9X4-H3uqQeg0VIZ6GZ9~1zQq5OZiTS~IC4TqqM7N6gzA20eMS0rK-5EKCtt9OrW~wo3LcGoqus0WxvFQslz73aFxgGCjupS~7LSfG6iDSKgnE9W4bC~fxeKw0BXxcsN0ATfsZtF2grPpjIEHk6ojmm4mjDy-Kx6PGjw197Vv9BZhEW~2VuQoXIHxOqGAehiep9DOkOraXl88q~2uzUmXF3SXRFrhNGR91v7LnRU9SBHXw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Outline of treatment strategies in the type I interferonopathies. Dependent on the underlying pathological mechanism, therapeutic approaches in the type I interferonopathies might include blocking the generation (e.g., using reverse transcription inhibitors: https://clinicaltrials.gov/ct2/show/NCT02363452), sensing (e.g., cGAS inhibition by hydroxychloroquine [An et al., 2015]), or signaling (e.g., TBK1 inhibition [Hasan et al., 2015]) of putative self–nucleic acids engaging the type I interferon innate immune machinery and blocking of interferon itself (e.g., with anti–type I interferon antibodies), the IFNAR receptor, or the signaling cascades distal to interferon ligand binding (e.g., by JAK1 inhibition [Frémond et al., 2016]).
